This book is the first to provide both a broad overview of the current methodologies being applied to drug design and in-depth analyses of progress in specific fields. It details state-of-the-art approaches to pharmaceutical development currently used by some of the world's foremost laboratories. The book features contributors from a variety of fields, new techniques, previously unpublished data, and extensive reference lists.
This book deals with predominantly synthetic chemical approaches to drug design and explores the use of structure-activity relationships in the design of novel inhibitors of ribonucleotide reductase. It describes the application of the tools of structural biology to pharmaceutical development.
